Ambrx company information, Employees & Contact Information

A general approach to site-specific antibody drug conjugates PNAS

Ambrx Announces Sale to Johnson & Johnson Yahoo Finance

Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update Investing News Network

Ambrx to Commence Trading on Nasdaq Business Wire

Ambrx Closes $200 million in Crossover Financing with Leading Healthcare Investors to Advance its Clinical and Preclinical Pipeline of Precision Biologics PR Newswire

J&J Buys Up Ambrx for $2B San Diego Business Journal

FDA grants Fast Track Designation to ARX517 for metastatic castration-resistant prostate cancer Urology Times

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn Pharmaceutical Technology

J&J deal cements Ambrx’s transformation | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

J&J to acquire ADC drug developer Ambrx for $2B BioPharma Dive

Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics PR Newswire

Ambrx Announces NovoCodex's Dosing of First Patient with ARX305, Ambrx's Investigational Antibody Drug Conjugate Targeting CD70 Investing News Network

Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments Yahoo Finance

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer Business Wire

Ambrx Soars on Synthetic ADC Linker Science San Diego Business Journal

Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment Investing News Network

Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugates PR Newswire

Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Conjugate Targeting CD70 Business Wire

Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors Investing News Network

Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer PR Newswire

The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma statnews.com

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy Yahoo Finance

Johnson & Johnson acquires Ambrx Biopharma for $2bn Pharmaceutical Technology

Johnson & Johnson to Acquire Clinical-Stage Antibody Drug Conjugate Company Ambrx for $2 Billion Inside Precision Medicine

Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics GlobeNewswire

FDA Awards Fast Track Designation to ARX517 for Metastatic Castration-Resistant Prostate Cancer OncLive

J&J beefs up ADC pipeline by acquiring Ambrx for $2B Fierce Biotech

J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion CNBC

ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen Fierce Biotech

Johnson & Johnson buys San Diego’s Ambrx Biopharma for $2B San Diego Union-Tribune

Uncertainty at Ambrx as biotech loses CEO, takes hard look at pipeline Fierce Biotech

PSMA targeting antibody-drug conjugate shows promise in mCRPC Urology Times

J&J to Purchase Antibody-Drug Conjugate Company Ambrx for $2 Billion BioSpace

Johnson & Johnson Pays $2 Billion for Ambrx To Boost Its Cancer Drug Pipeline Investopedia

Johnson & Johnson's Acquisition Of Ambrx Biopharma: Hold Through It (NASDAQ:AMAM) Seeking Alpha

USC Norris Comprehensive Cancer Center launches global clinical trial testing potential therapy for aggressive type of breast cancer Keck Medicine of USC

Johnson & Johnson: $2bn Buyout Of Ambrx Is Good Business (NYSE:JNJ) Seeking Alpha

Role of tRNA Orthogonality in an Expanded Genetic Code ACS Publications

Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today? InvestorPlace

Resilient Biopharma Leadership With Ambrx's Dan O'Connor Bioprocess Online

J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx Acquisition MedCity News

Ambrx cuts 15% of staff and dumps lead HER2 asset after 'strategic review' Fierce Biotech

Johnson & Johnson to acquire ADC specialist Ambrx Biopharma for approximately $2bn PMLiVE

BMS-Ambrx collab runs out of steam after FA relaxin med canned Fierce Biotech

ADCs as biological missiles for targeted therapies Pharmaceutical Technology

J&J sees deal ‘opportunities’ in neuroscience and immunology post-Ambrx buy Fierce Biotech

Chinese Consortium Acquires Ambrx For Undisclosed Sum Asian Scientist Magazine

Strategies to Mitigate Technology Transfer and Clinical Manufacturing Risks: Downstream Purification Case Studies BioProcess International